GPS Cancer™: Building Momentum With Healthcare Payors
GPS Cancer™ is a unique, comprehensive molecular test offered by NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics, providing oncologists with a detailed molecular profile of a patient’s cancer to inform personalized treatment strategies. For more information, visit the GPS Cancer solution page.
GPS Cancer – The Era of Clinical Proteomics is Here
In January 2016, Independence Blue Cross became the first commercial payor to make GPS Cancer testing available to its members.
“Independence Blue Cross is committed to bringing state-of-the-art advances in oncology to our members and making care accessible and affordable. Decisions around cancer care are complex and personal. We’re focused on supporting Independence members and their oncologists by offering coverage for this innovative approach to treating cancer. Whole genome sequencing is one more option to help inform a personalized, effective treatment plan.”Daniel J. Hilferty
In May 2016, coverage for GPS Cancer further expanded, with Sanford Health Plan becoming the second commercial insurer to cover the test.
“At Sanford Health, we are dedicated to offering our employees affordable and accessible high-quality care. Not only is GPS Cancer testing a novelty approach to cancer care, but it offers our employees – and their families – what we believe to be the best coverage for receiving improved cancer treatment options. As one of the founding members of the National Immunotherapy Coalition and Pediatrics Consortium, we are committed to the Cancer Breakthroughs 2020 program and its initiatives to win the war on cancer.”Richard Adcock
In addition to coverage by commercial health plans, Bank of America, Sanford Health and Phoenix Children’s Hospital have become the nation’s first self-insured employers to cover GPS Cancer for various cancers, helping their employees—and their families—to gain better insight and treatment strategies in optimizing cancer therapy.